Abstract #4379
Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a Multicenter Intra-individual Crossover Comparison of Gadobutrol with Gadoteridol (The TRUTH study)
Martin P Smith 1 , Kenneth R Maravilla 2 , Stefano Bastianello 3 , Eva Bueltmann 4 , Toshinori Hirai 5 , Tiziano Frattini 6 , Cesare Colosimo 7 , and Gianpaolo Pirovano 8
1
Department of Radiology, Beth Israel
Deaconess Medical Center, Boston, MA, United States,
2
University
of Washington, WA, United States,
3
Neuroradiology
Department, University of Pavia, Pavia, Italy,
4
Oberartzin
Institut fur Diagnostiche und Interventionelle
Neuroradiologie, Hannover, Germany,
5
Kumamoto
University, Kumamoto, Japan,
6
Ospedale
Valduce, Como, Italy,
7
Policlinico
Agostino Gemelli, Rome, Italy,
8
Bracco
Diagnostics Inc., Monroe, NJ, United States
Two-hundred-twenty nine patients with suspected brain
tumors underwent two identical, randomized MRI exams at
1.5T; one enhanced with 0.1 mmol/kg gadoteridol
(ProHance) and the other with 0.1 mmol/kg gadobutrol
(Gadavist). Three blinded readers evaluated matched
image sets for qualitative (lesion extent, delineation,
morphology, enhancement, global preference) and
quantitative (LBR, % enhancement) lesion enhancement and
randomized, unmatched image sets for accuracy in lesion
diagnosis vs. final clinical diagnosis. No significant
differences were noted by any reader for any end-point.
The results confirm that the higher concentration of the
Gadavist formulation has no impact on routine
morphologic imaging of brain tumors.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
